Extendicare (TSE:EXE – Get Free Report) was upgraded by analysts at BMO Capital Markets from a “market perform” rating to an “outperform” rating in a research note issued on Thursday,BayStreet.CA reports. The firm presently has a C$24.00 price target on the stock, up from their prior price target of C$21.00. BMO Capital Markets’ price target would indicate a potential upside of 7.58% from the stock’s current price.
EXE has been the topic of several other reports. National Bankshares upped their price target on Extendicare from C$21.50 to C$24.50 and gave the company an “outperform” rating in a research report on Wednesday. TD Securities boosted their price objective on shares of Extendicare from C$15.00 to C$19.00 in a research note on Thursday, November 13th. Cormark increased their target price on shares of Extendicare from C$25.00 to C$30.00 in a research note on Wednesday. CIBC raised their price target on shares of Extendicare from C$18.00 to C$22.00 in a report on Thursday, November 13th. Finally, Canaccord Genuity Group boosted their price target on shares of Extendicare from C$20.00 to C$22.50 in a research report on Thursday. Three research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of C$23.86.
Get Our Latest Stock Report on Extendicare
Extendicare Stock Performance
About Extendicare
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Featured Articles
- Five stocks we like better than Extendicare
- What is a Dividend King?
- The Nuclear Revival Is Real: SMR Stocks Flash Buy Signals After DOE Push
- What is the Euro STOXX 50 Index?
- Boeing’s Bullish Breakout: Is This Rally Cleared for Takeoff?
- What is the FTSE 100 index?
- Wolfspeed Just Got a $698 Million Lifeline—Here’s Why That Changes Everything
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.
